European Leukodystrophies Association (ELA)
Leukodystrophies are a group of rare genetic diseases that destroy the central nervous system in children and adults. Symptoms vary widely with each disease but can include a loss of motor function for many. These diseases affect between 20 and 40 newborn babies in Europe each week. Thankfully, Nu Skin Europe, Middle East and Africa (EMEA) have chosen to partner with a non-profit organisation called European Leukodystrophies Association (ELA) to help raise funds for the first worldwide clinical trial of new therapeutic advancements on one leukodystrophy’s form.
TThroughout 2020 and 2021, Nu Skin EMEA will help raise funds in the following ways:
ELA works to assist, and support families affected by leukodystrophies, stimulate the development of medical research and raise public awareness in Europe and further abroad.
The funds that Nu Skin EMEA collects will go towards ELA’s €500,000 contribution, which will be used to support the first worldwide clinical trial of new therapeutic advancements on one leukodystrophy’s form. The goals of this clinical trial are to increase scientific understanding and to find ways to prevent, treat, and, ultimately provide a cure.